Laird Norton Wetherby Wealth Management LLC Makes New Investment in Inhibrx, Inc. (NASDAQ:INBX)

Laird Norton Wetherby Wealth Management LLC acquired a new position in Inhibrx, Inc. (NASDAQ:INBX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 30,656 shares of the company’s stock, valued at approximately $472,000.

Other hedge funds also recently made changes to their positions in the company. PNC Financial Services Group Inc. acquired a new stake in shares of Inhibrx during the fourth quarter worth approximately $28,000. Natixis acquired a new stake in Inhibrx in the fourth quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. acquired a new stake in Inhibrx in the fourth quarter valued at approximately $47,000. New York State Common Retirement Fund acquired a new stake in Inhibrx in the fourth quarter valued at approximately $53,000. Finally, Corebridge Financial Inc. acquired a new stake in Inhibrx in the fourth quarter valued at approximately $89,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Stock Up 10.9%

Shares of INBX stock opened at $12.02 on Friday. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $34.73. The firm’s fifty day simple moving average is $12.66 and its 200 day simple moving average is $13.69.

Inhibrx (NASDAQ:INBX) last issued its earnings results on Wednesday, May 14th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($2.55) by ($0.25). On average, analysts anticipate that Inhibrx, Inc. will post 104.88 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research note on Thursday.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.